Study of Nutritional Supplement Shakes in People About to Receive Their Debulking Surgery for Ovarian Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03956095|
Recruitment Status : Recruiting
First Posted : May 20, 2019
Last Update Posted : July 11, 2019
The purpose of this study is to find out if it is possible to establish a nutritional support program for people who are scheduled to receive primary debulking surgery.
Design: This will be a prospective observational study to assess the feasibility of implementing a preoperative nutrition supplementation program.
|Condition or disease||Intervention/treatment|
|Debulking Surgery for Ovarian Cancer||Dietary Supplement: nsure Surgery Immunonutrition Shake supplements|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Preoperative Nutrition Intervention for Patients Undergoing Primary Surgical Debulking of Ovarian Cancer: A Feasibility Study|
|Actual Study Start Date :||May 16, 2019|
|Estimated Primary Completion Date :||May 2021|
|Estimated Study Completion Date :||May 2021|
Ensure Surgery Immunonutrition Shake supplements
Participants will be provided with and instructed to drink three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
Dietary Supplement: nsure Surgery Immunonutrition Shake supplements
Three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
- rate of patient participation [ Time Frame: 30 days after surgery ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03956095
|Contact: Vance Broach, MDemail@example.com|
|Contact: Kara Long Roche, MD||212-639-7043|
|United States, New York|
|Memorial Sloan Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Vance Broach, MD 212-639-6876|
|Contact: Kara Long-Roche, MD 212-639-7043|
|Principal Investigator: Kara Long-Roche, MD|
|Principal Investigator:||Vance Broach, MD||Memorial Sloan Kettering Cancer Center|